Moderna PE ratio MRNA

Share price divided by earnings per share over the last twelve months, since 2021.

Today, Oct 23, 2026: n/m; losses over the last year
Last meaningful: 28.7×; Nov 2023
5-year median: 9.9×
5-year range: 3.6× to 283×
Peer median: 25.8×

Moderna has no meaningful PE ratio today: it lost $7.99 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in Nov 2023, at 28.7×.

On the days it had one over the last 5 years, its median was 9.9×, from 3.6× in Sep 2022 to 283× in Jul 2021.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	28.7×	5.0×	42.4×
2022	6.5×	3.6×	13.1×
2021	15.6×	14.2×	283×

Against its peers

Companies in Biotechnology nearest Moderna's size, closest first, today.

Company	PE ratio
MRNAModerna	n/m
REGNRegeneron Pharmaceuticals	19.9×
VRTXVertex Pharmaceuticals	30.5×
ONCBeOne Medicines	67.6×
ALNYAlnylam Pharmaceuticals	37.8×
UTHRUnited Therapeutics	21.0×
INCYIncyte	14.7×
EXELExelixis	20.3×
NBIXNeurocrine Biosciences	20.9×
HALOHalozyme Therapeutics	37.5×
TECHBIO-TECHNE	63.1×
Peer median	25.8×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Moderna

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.